Colorado BioScience Association Celebrates State’s Collaborative Nature

New Magazine Offers In-Depth Financing Data and Insights on Medical Device and Drug Approvals

DENVER--()--Colorado BioScience Association (CBSA) today launched the new issue of its annual magazine, BioScience Colorado: Collaborative by Nature, at this week’s 2019 BIO International Convention in Philadelphia. The 2019-2020 magazine highlights Colorado’s reputation for collaboration, profiles companies focused on engaging patients in the product design and development process, and details the successes of the state-supported Advanced Industries grant program.

Jennifer Jones Paton, President and CEO of CBSA, says:
“Colorado’s life science ecosystem stands apart because of our commitment to solving business challenges together. Our member companies, academic and research institutions, and partners collaborate to improve the lives of patients here in Colorado and around the world. We titled our new BioScience Colorado magazine Collaborative by Nature because of the close working relationships in our ecosystem.”

BioScience Colorado 2019-2020: Collaborative by Nature provides comprehensive data on the state’s life science industry, with detailed information on topics of interest.

Advanced Industry Grants
Since inception, the state funded Advanced Industries Grant program has awarded 413 grants to life science companies, creating 773 direct jobs, 79 new companies and $551.7 million in follow-on grants and investments.

Financing
Colorado life science companies raised $1 billion in 2018. The magazine breaks down investments by company name and deal type.

Medical Device Approvals
In 2018, 219 medical devices and diagnostics developed by Colorado companies received 510(K) approval from the FDA, and 5 achieved a PMA designation. In-vitro diagnostics, cardiovascular, and orthopedics were the largest categories of medical devices in approved or investigational status.

Pharmaceutical Trials by Therapy Area
Colorado pharmaceutical companies participated in 1,140 clinical trials in 2018. Top drugs and trials by therapy area included: Oncology, central nervous system and infectious disease.

Emily Roberts, Vice President of CBSA, says:
“The annual magazine provides new insights on the breakthroughs happening here and in-depth information on recent investments, grants, drug and device trials, and product approvals. CBSA Members and partners use the annual magazine to share our life science success stories with prospective investors, potential partners and out-of-state talent considering a move to Colorado.”

CBSA members will receive a copy of the magazine via mail. Additional copies are available at any CBSA event or by request. An electronic version of the magazine is available on the CBSA website.

About the Colorado BioScience Association

Colorado BioScience Association champions life science. We serve as the hub of Colorado’s thriving bioscience sector by connecting innovators to funding, infrastructure, research and talent. From promising young companies to established corporations and institutions, we provide opportunities for networking, education and professional development. We grow the bioscience workforce and lead business expansion policies to advance the industry in our state. CBSA represents more than 350 member organizations, including biotechnology, pharmaceutical, medical device, diagnostic, ag bio and mobile digital health companies, research and academic institutions and service providers. Learn more about us at http://www.cobioscience.com.

Connect with CBSA: Twitter @COBioscience, Facebook and LinkedIn.

Contacts

Sheliah Reynolds
Primavera Group for Colorado BioScience Association
(720) 289-4739
sheliah@theprimaveragroup.com

Release Summary

CBSA highlights the state's collaborative culture and releases new data on financings and FDA approvals in its annual magazine.

#Hashtags

Contacts

Sheliah Reynolds
Primavera Group for Colorado BioScience Association
(720) 289-4739
sheliah@theprimaveragroup.com